News|Webcasts|January 18, 2024

Navigating Success During a Rare Disease Product Launch

Author(s)Herspiegel

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

Join us to learn about current trends in rare disease drug development and commercialization, as well as implications for rare disease product launches. In this webcast, we share learnings from our 125+ pharmaceutical product launches, insights to identify risk and strategies to mitigate them, and best practices for launch timelines and stage gates.

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Event Overview:

Rare disease products account for half of all US FDA approvals, most with fast-track designations, which means compressed launch timelines and increasingly competitive markets with smaller patient populations. Organizations need to start their project journey 24-36 months prior to approval to gain a comprehensive understanding of the patient journey, educate providers effectively, foster advocacy, and establish a clear path to diagnosis and access to treatment. Early alignment to a cross-functional strategy supports decisions about prioritizing and judiciously allocating limited resources pre-approval.

If you are developing assets for rare disease indications, take advantage of this presentation to learn how to ensure your launch is set up for success.

Key Learning Objectives:

  • Trends in rare disease drug development and commercialization
  • Unique considerations for major commercial decisions in rare disease markets
  • Identification of challenges and effective strategies to address them
  • Best practices for launch timelines and stage gates for Medical Affairs, Market Access, and Commercial perspectives

Who Should Attend:

  • CEOs, Chief Commercial Officers, Launch Leadership, Marketing Heads, EVPs of Marketing of organizations that are developing therapies for rare disease conditions.

Speakers:

Kapil Raina, MD
Principal, Market Access
Herspiegel

Brian Williams
SVP, Commercial Strategy and Execution
Herspiegel

Chris Zealey, MSc
Principal, Science and Strategy
Sixsense Strategy Group, a Herspiegel Company

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.